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OBJECTIVE—Islet transplantations have been performed clin-
ically, but their practical applications are limited. An extensive
effort has been made toward the identiﬁcation of pancreatic
-cell stem cells that has yielded many insights to date, yet
targeted reconstitution of -cell mass remains elusive. Here, we
present a mouse model for inducible and reversible ablation of
pancreatic -cells named the PANIC-ATTAC (pancreatic islet
-cell apoptosis through targeted activation of caspase 8) mouse.
RESEARCH DESIGN AND METHODS—We efﬁciently induce
-cell death through apoptosis and concomitant hyperglycemia
by administration of a chemical dimerizer to the transgenic mice.
In contrast to animals administered streptozotocin, the diabetes
phenotype and -cell loss are fully reversible in the PANIC-
ATTAC mice, and we ﬁnd signiﬁcant -cell recovery with nor-
malization of glucose levels after 2 months.
RESULTS—The rate of recovery can be enhanced by various
pharmacological interventions with agents acting on the gluca-
gon-like peptide 1 axis and agonists of peroxisome proliferator–
activated receptor-. During recovery, we ﬁnd an increased
population of GLUT2
/insulin
 cells in the islets of PANIC-
ATTAC mice, which may represent a novel pool of potential
-cell precursors.
CONCLUSIONS—The PANIC-ATTAC mouse may be used as an
animal model of inducible and reversible -cell ablation and
therefore has applications in many areas of diabetes research
that include identiﬁcation of -cell precursors, evaluation of
glucotoxicity effects in diabetes, and examination of pharmaco-
logical interventions. Diabetes 57:2137–2148, 2008
D
iabetes is an epidemic affecting 180 million
people worldwide with rising prevalence (1).
Successful islet transplantation with the Edm-
onton protocol was considered a signiﬁcant
step toward a cure (2). However, because of the scarcity of
available islets and limited viability of transplanted islets,
this procedure has not yet found widespread application.
Extensive efforts have been directed toward identifying
pancreatic -cell stem cells for transplantation and ap-
proaches to stimulate -cell regeneration.
In the past, the potential -cell precursors have been
identiﬁed among embryonic stem cells, ductal cells, acinar
cells, and nonendocrine epithelial cells (3–7). More re-
cently, the proliferation of pre-existing -cells has been
shown to be the major source of -cell regeneration in
lineage tracing studies (8). The mechanisms of -cell
regeneration therefore remain controversial, and different
methodologies and animal models may be at the source of
these inconsistent observations.
Both in vitro islet culture and diabetic animal models
have been used extensively in characterization of pancre-
atic -cell death and regeneration and identiﬁcation of
-cell precursors. However, the ﬁndings gained from islet
cultures in vitro cannot always be extrapolated to the in
vivo situation because of the complexity of -cell physiol-
ogy. Current in vivo pancreas injury models include toxin
administration, pancreatectomy, and ductal ligation. Stud-
ies using these models have provided valuable insights for
physiological and pathophysiological regulation of -cells.
However, these animal models use acute, extreme, and
nonphysiological insults, and none of them show signiﬁ-
cant -cell recovery after injury.
In the present study, we describe a pancreas injury
model with inducible and reversible -cell ablation. In the
current transgenic mouse model, the PANIC-ATTAC (pan-
creatic islet -cell apoptosis through targeted activation of
caspase 8) mouse, -cell death is induced in a speciﬁc and
well-deﬁned manner through treatment of a chemical
dimerizer. Importantly, the PANIC-ATTAC mice show ex-
tensive -cell regeneration and normalization of glucose
levels after treatment. We found an increased population
of GLUT2
/insulin
 cells, which may serve as -cell
precursors. The PANIC-ATTAC mouse model has the
potential to be highly informative in many areas of diabe-
tes research and provides an opportunity to characterize
-cell pathophysiology during diabetes progression.
RESEARCH DESIGN AND METHODS
Generation of the PANIC-ATTAC transgenic mice. The rat insulin pro-
moter was used to drive the expression of FK506 binding protein (FKBP)–
caspase 8 fusion protein. A PCR fragment containing FKBP-caspase 8 and
3-untranslated region was cloned into pCR4TA (Invitrogen) and then sub-
cloned into the promoter vector. After linearization, the DNA preparation was
injected into FVB embryos. Positive lines were identiﬁed by PCR genotyping
(9). All animal protocols were approved either by the Institute for Animal
Studies of the Albert Einstein College of Medicine or by the Institutional
Animal Care and Use Committee of University of Texas Southwestern Medical
Center at Dallas.
Tests and assays. For oral glucose tolerance test (OGTT), mice were fasted
for 2.5 h before glucose oral gavage at 2.5 mg/kg body wt. Tail blood was
drawn for glucose measurements by an oxidase-peroxidase assay (Sigma).
The insulin levels were determined by an insulin ELISA assay (Millipore). For
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DIABETES, VOL. 57, AUGUST 2008 2137intraperitoneal glucose tolerance tests (IPGTTs), mice were fasted for 5 h, and
glucose was administrated at a concentration of 2.5 mg/kg body wt. The
pancreatic insulin content was measured as described previously (10). For
insulin tolerance tests (ITTs), mice were fasted for 2.5 h before administration
of insulin at 1 IU/kg body wt intraperitoneally (Novo Nordisk).
Dimerizer administration. The dimerizer AP20187 was administrated to 2-
to 3-month-old animals according to the manufacturer’s recommendations
(Ariad Pharmaceuticals). For hemizygous PANIC-ATTAC mice, dimerizer of
0.2 g/g body wt was injected twice a day at 12:00 P.M. and 6:00 P.M. every other
day for a total of eight injections. For homozygous PANIC-ATTAC mice, a
single injection (0.2 or 0.3 g/g body wt) was performed at 12:00 P.M.
Histology. Pancreata were dissected and ﬁxed in 10% buffered formalin
overnight. Parafﬁn sections of 5 m were processed for histology. For
immunoﬂuorescence, sections were incubated with primary antibodies for
24 h and subsequently decorated with secondary antibodies for1ha troom
temperature. Antibodies used include guinea pig anti–swine insulin (1:500;
B22.4 B22.0 B23.2
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FIG. 1. Generation of PANIC-ATTAC transgenic mice. A: Transgene expression in all the three founder transgenic lines. Total RNA from whole
pancreas was isolated and processed for reverse transcription. The PCR ampliﬁcation results are shown for the transgene, insulin, and GAPDH,
with the latter two as loading controls. B: Quantitative PCR analysis to determine the expression levels of the transgene relative to insulin in
three positive founder lines. n  5 per mouse line. *P < 0.001. C: Tissue distribution of the transgene in the founder line B23.2. GAPDH was used
as a loading control. Note that the relative expression of transgene in pancreas is higher compared with hypothalamus due to the partial
degradation of RNA during preparation indicated by the low GAPDH signal in the pancreas.
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2138 DIABETES, VOL. 57, AUGUST 2008DAKO), rabbit anti–human glucagon (1:250; Zymed), rabbit anti-GLUT2
(1:200; Chemicon), rabbit anti–PDX-1 (1:200; provided by Dr. Raymond
MacDonald), goat anti–PDX-1 (1:1,000; provided by Dr. Klaus Kaestner), rat
anti–mouse Ki67 (1:100; DAKO), rabbit anti-MafA (1:1,000; Bethyl Labs),
donkey anti–guinea pig IgG–ﬂuorescein isothiocyanate (1:250; Jackson Immu-
noresearch), and donkey anti–rabbit IgG-Cy3 (1:500; Jackson Immunore-
search). Images were taken on a Leica TCS SP5 confocal microscope. For
immunohistochemistry, sections were incubated with primary antibodies for
24 h at 4°C. Sections were then incubated with biotinylated secondary
antibodies (1:500 anti–guinea pig IgG and 1:200 anti–rabbit IgG [DAKO]) for
1 h at room temperature, and reaction was developed with ABC reagent
(Vector Laboratories). Images were acquired with Coolscope (Nikon). To
visualize apoptotic nuclei, transferase-mediated dUTP nick-end labeling
(TUNEL) staining was performed using an in situ cell death detection kit
(Roche) (11). To measure -cell mass, a full-print pancreas section was
chosen for immunostaining of insulin. The whole area of the pancreas was
calculated by ImageJ. The sum area of all islets was calculated with the
automatic measurement tool of AxioVision 4.6 (Carl Zeiss). To study the role
of the hypothalamus, mice were perfused with 10% formalin, and the brain
was removed for overnight ﬁxation. After 24-h incubation in 20% sucrose,
hypothalamus free-ﬂoating sections (25 m) were produced using a freezing
microtome. Hypothalamus sections were mounted on glass slides, air dried,
and processed for TUNEL staining.
Treatments. For streptozotocin (STZ) administration, FVB mice received a
single intraperitoneal dose (175 mg/kg) of freshly prepared STZ (Sigma). For
Exendin-4 administration, male hemizygous transgenic PANIC-ATTAC mice
were fed with high-fat diet 4 weeks before hyperglycemic induction. Two
doses of exendin-4, 3.3 or 10 g/kg body wt (pk), were selected for daily
injection at 4:00 P.M. Postprandial glucose and body weight were monitored
periodically. For peroxisome proliferator–activated receptor (PPAR)- ago-
nist administration, the 2-(2-(4-phenoxy-2-propylphenoxy)ethyl)indole-5-ace-
tic acid compound, a gift from Merck Research Laboratories (12), was mixed
with powdered food at 75 g/g. The average dose for mice is 10 mg/kg body
wt. For the sitagliptin studies (13), male homozygous PANIC-ATTAC mice
were induced to hyperglycemia by three continuous injections of dimerizer
(0.2 g/g body wt) 24 h apart and put on diet mixed with compound (7.8 g
active ingredient/kg chow diet) (Research Diets). Postprandial glucose and
body wt were monitored periodically. An OGTT was conducted at day 75 of
sitagliptin treatment. Serum samples obtained from terminal bleeds (post-
prandial) at day 80 were used for active glucagon-like peptide 1 (GLP-1) level
determination using an active GLP-1 ELISA assay (Millipore).
Statistical analysis. Results were presented as means  SE. Statistical
analysis was performed with the Student’s t test except OGTT, ITT, and
glucose proﬁling results, which were done by two-way ANOVA and subse-
quent Tukey’s test. Signiﬁcance was accepted at P  0.05.
RESULTS
Generation of transgenic PANIC-ATTAC mice. To
ablate pancreatic -cells in a targeted and inducible way,
we have taken advantage of the cell-speciﬁc expression of
a FKBP-caspase 8 fusion protein. This approach relies on
a system developed by Clackson et al. (14) that uses a
mutated form of FKBP domain which selectively and
avidly binds a FK506 analog but not the endogenous
ligand. This interaction can bring two mutant FKBP do-
mains in close proximity, thereby effectively inducing
dimerization of any passenger protein attached to the
FKBP moiety. We fused the mutant FKBP domain to
caspase 8, which can lead to apoptosis after dimerization
(15). The expression of this FKBP-caspase 8 protein does
not convey a phenotype in its monomeric form. However,
on administration of a chemical that forces the dimeriza-
tion of caspase 8 through interaction with the FKBP
domain, caspase 8 is activated, and the apoptotic cascade
is initiated (16). We have previously described a mouse
model that carries such a transgene under the control of
an adipocyte-speciﬁc promoter (fat apoptosis through
targeted activation of caspase 8 [FAT-ATTAC]) in which
we were able to inducibly ablate adipocytes (9). Here, we
put the gene encoding this fusion protein under the control
of the rat insulin promoter. By RT-PCR analysis, we found
that all three lines expressed the transgene (Fig. 1A). By
quantitative PCR, line B23.2 showed the highest expres-
sion and was chosen for further studies (Fig. 1B). We refer
to this mouse model as PANIC-ATTAC.
To evaluate tissue-speciﬁc expression, RT-PCR analysis
was performed on 11 tissues of a transgenic mouse. As
expected, the pancreas showed high level expression (Fig.
1C). Several reports in the literature have indicated that
the rat insulin promoter cassette can convey expression in
the brain, which is consistent with what we found here
(17). Expression can be seen in a number of regions (S.
Chua, personal communication; data not shown). Impor-
tantly, however, activation of the hypothalamic caspase 8
does not seem to occur under conditions when the pan-
creatic -cells are efﬁciently ablated because no evidence
of apoptosis in hypothalamic neurons could be found under
these conditions (supplementary Fig. 1, available in an online
appendix [available at http://dx.doi.org/10.2337/db07-1631]).
This could be due to the resistance of neurons to caspase-
8–mediated apoptosis or to the inability of the dimerizer
compound to effectively cross the blood-brain barrier. We
were unable to trigger neuronal apoptosis even after direct
intracerebroventricular administration of the dimerizer (not
shown). We therefore believe that it is very unlikely that the
effects reported below would be inﬂuenced by events trig-
gered in the brain on dimerizer treatment.
Characterization of mice hemizygous for the PANIC-
ATTAC transgene. Wild-type and transgenic mice are
phenotypically indistinguishable for body weight (data not
shown), glucose and insulin levels during OGTT, pancre-
atic insulin content, and islet architecture (Fig. 2A). We
concluded that the mice had no measurable baseline
phenotype.
A cohort of wild-type and transgenic animals was cho-
sen for treatment with the dimerizer compound of eight
injections. An OGTT was performed 8 days after the
initiation of treatment. Interestingly, despite identical ge-
netic background and treatment regimen, the transgenic
mice could be grouped into low responders, whose glu-
cose levels were elevated but still 300 mg/dl, and high
responders, whose glucose levels tended to be 	400
mg/dl. One possible reason for this heterogeneous re-
sponse may be the subtle difference of actual dimerizer
delivery between animals. A similar phenomenon has been
found in partial pancreatectomy animal models in which
subtle variations in the proportion of pancreatic tissue
removed resulted in two different degrees of hyperglyce-
mia (18). The transgenic mice were therefore classiﬁed
into two groups and analyzed separately. Both groups
displayed high glucose levels during the OGTT with high
responders displaying bigger excursions (Fig. 2B). None of
the hyperglycemic PANIC-ATTAC animals displayed much
of insulin release during OGTT. Total pancreatic insulin
content was reduced by 	75% in low responders and
	90% in high responders. Correspondingly, the damage at
the level of islets was quite apparent by histology. From
these and other quantitative assessments of the -cell
mass, it is clear that hyperglycemia manifests only after a
substantial portion of -cell mass is eliminated (19).
We were surprised to see that on allowing these mice to
recover for 
8 weeks, the glucose tolerance during an
OGTT showed improvements compared with the initial
hyperglycemic conditions (Fig. 2C). Insulin release during
the OGTT was, however, still impaired even though total
pancreatic insulin content approached wild-type levels in
the low responders and dramatically increased in the high
responders. On analysis of fasting glucose levels, it is
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FIG. 2. Characterization of hemizygous PANIC-ATTAC transgenic mice. A: OGTT and pancreatic insulin content of wild-type and hemizygous
PANIC-ATTAC mice before dimerizer administration. For OGTT, n  6 per group. For insulin content, n  5 of wild type and n  4o f
PANIC-ATTAC. A representative immunoﬂuorescent image for insulin (green), glucagon (red), and nuclei (blue) is shown. Scale bar  50 m.
B: OGTT and pancreatic insulin content of wild-type and hemizygous PANIC-ATTAC mice 8 days after administration of dimerizer (time of onset
hyperglycemia). In glucose measurement during OGTT, all comparisons including wild type (n  5) vs. low responders (L-PANIC) (n  3),
L-PANIC vs. high responders (H-PANIC) (n  6), and wild type vs. H-PANIC are statistically signiﬁcant except wild type vs. L-PANIC at time 180
min. For the analysis of insulin levels during OGTT, the differences between wild type and L-PANIC at 15 min, wild type and H-PANIC at 15 min,
and wild type and H-PANIC at 30 min are signiﬁcant. For insulin content, n  5 of wild type, n  4 of L-PANIC, and n  3 of H-PANIC. A
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2140 DIABETES, VOL. 57, AUGUST 2008apparent that glucose control is normalized in all mice on
recovery (Fig. 2D). A more detailed analysis of fasting
glucose levels during the entire period shows recovery
that even the high responders manifest (Fig. 2E). These
results suggest that we can effectively induce -cell abla-
tion and hyperglycemia in hemizygous PANIC-ATTAC
animals and that, more importantly, the mice can restore
euglycemic control after recovery.
The treatment regimen described above established the
conditions under which we can obtain both low respond-
ers and high responders. We aimed to ﬁnd conditions that
would render the -cells more susceptible to apoptosis.
Lipotoxicity has been implicated in the dysfunction of
-cells during diabetes progression (20). When exposed to
a normal chow diet, the majority of the mice convert to
low responders after dimerizer treatment, with only 
30%
displaying a high response. On exposure to high-fat diet
for 5 or 10 weeks before dimerizer treatment, a much
higher percentage of mice was converted to high respond-
ers by the same injections (Fig. 3A). To assess the effects
of high-fat diet on the transgene expression (under the
control of rat insulin promoter II), we isolated islets and
performed quantitative RT-PCR after exposure to high-fat
diet. We found that high-fat diet treatment increases the
transgene expression (Supplementary Fig. 2). Although
transgene expression does play a role under these condi-
tions, there may also be a contribution of lipid accumu-
lation in -cells under these conditions. The more
susceptible phenotype may therefore be a combination of
increased transgene expression and lipotoxicity.
Exendin-4 treatment improves the recovery after a
massive -cell insult. A number of powerful antidiabetes
drugs have recently become available, many of which take
advantage of the GLP-1 axis. Exendin-4 is a potent and
long-lived GLP-1 receptor agonist (21) that has been
shown to increase -cell mass and to improve glucose
tolerance (22). We chose severely challenged PANIC-
ATTAC mice (glucose levels 	500 mg/dl) and treated them
with exendin-4. As seen in Fig. 3B, dimerizer treatment
and subsequent exendin-4 treatment did not have an
impact on glucose levels in wild-type animals. However,
PANIC-ATTAC mice that were exposed to low and high
doses of exendin-4 showed a dose-dependent improve-
ment of hyperglycemia over a period of 2 weeks. Corre-
spondingly, the PANIC-ATTAC mice in the 10 pk group
showed lower glucose levels during an OGTT (Fig. 3C) but
remained deﬁcient in glucose-stimulated insulin secretion
(GSIS) (Fig. 3D). The potent effects of exendin-4 treatment
were seen when total pancreatic insulin content was
measured (Fig. 3E), which was further corroborated by
islet histology (Fig. 3F).
Characterization of homozygous PANIC-ATTAC
transgenic mice. Although mice hemizygous for the
PANIC-ATTAC transgene require multiple injections of
dimerizer and still fall into “moderate” and “full” responder
categories, we wanted to probe the effects of doubling the
transgene dosage, i.e., rendering the mice homozygous at
the transgene loci. At baseline, the homozygous mice
revealed no differences compared with wild-type animals
(Fig. 4A). However, the higher potency of doubling trans-
genic dosage became apparent when a single injection of
dimerizer compound at only 0.2 g/g body wt was sufﬁ-
cient to trigger a uniform response and homogeneous
hyperglycemia in all mice (Fig. 4B). Phenotypically, the
mice behaved as expected, with severe hyperglycemia
during an OGTT, ineffective GSIS, low pancreatic insulin
content, and very few insulin
 cells in islets (Fig. 4B). To
conﬁrm that the decrease of pancreatic insulin content is
due to -cell loss, we quantiﬁed the -cell mass 8 days
after initiation of dimerizer treatment. We detected a
10-fold decrease of -cell mass, consistent with the results
obtained by assessing the decrease in pancreatic insulin
content (Supplementary Fig. 3). As with all models target-
ing -cells in vivo, we cannot formally rule out the
possibility of a downregulation of insulin expression in
otherwise mature -cells that may give a false impression
of -cell loss. However, the widespread apoptotic -cells
found in islets, the absence of MafA
/insulin
 cells, and
the disrupted islet architecture suggest -cell death is the
most likely cause of decreased pancreatic insulin content
and hyperglycemia. Despite the aggressive nature of the
ablation, no lethality has been found, and these mice
managed to mount an effective recovery as evident during
an OGTT, by pancreatic insulin content, and by histology
(Fig. 4C). The recovered glucose tolerance during an
OGTT is accompanied by a defective insulin response. To
assess whether differences in gastric absorption are in-
volved, we performed IPGTT after5ho ffasting. As with
OGTT, we found that during IPGTT, the glucose tolerance
is improved, whereas glucose-stimulated insulin secretion
remains defective (Supplementary Fig. 4).
Although the initial effects shown here were obtained
with a single dose of dimerizer, the homozygous mice also
displayed a dose-dependent reduction of pancreatic insu-
lin content, offering the possibility to ablate a predeter-
mined number of -cells in a reproducible and uniform
manner (Fig. 4D). Focusing on the fasting glucose levels
further corroborated that the mice improved their glucose
control after recovery (Fig. 4E). A more reﬁned analysis of
the fasting glucose levels showed that the mice restored
euglycemia within 
6 weeks after the onset of hypergly-
cemia (Fig. 4F).
To formally demonstrate that the -cell death triggered
by forced dimerization of caspase 8 is caused by apopto-
sis, we performed transferase-mediated dUTP nick-end
labeling (TUNEL) staining. Although relatively limited
apoptosis was seen 4 h after dimerizer treatment, TUNEL

cells (red) were clearly visible 24 h after treatment,
particularly in the more stringent homozygous setting (Fig.
4G). The disorganized islet structure and decreased insu-
lin
 -cells in homozygous transgenic mice indicate that
the peak apoptotic response may occur before 24 h,
representative immunoﬂuorescent image for insulin (green), glucagon (red), and nuclei (blue) is shown. Scale bar  50 m. *P < 0.05, **P <
0.001. C: OGTT and pancreatic insulin content of wild-type and hemizygous PANIC-ATTAC mice 64 days after administration of dimerizer when
serum glucose returns to normal level. For glucose measurements during OGTT, the comparisons between wild type (n  3) versus L-PANIC (n 
4) and wild type versus H-PANIC (n  4) show signiﬁcant differences at 30, 60, and 120 min. For insulin measurements during OGTT, the
differences between wild type (n  3) and L-PANIC (n  3) and wild type and H-PANIC (n  3) during the entire course are signiﬁcant. For insulin
content, n  8 of wild type, n  4 of L-PANIC, and n  5 of H-PANIC. A representative immunoﬂuorescent image for insulin (green), glucagon
(red), and nuclei (blue) is shown. Scale bar  50 m. *P < 0.05, **P < 0.001. D: Fasting glucose levels of wild type, L-PANIC, and H-PANIC mice
before dimerizer treatment, at the onset of hyperglycemia, and after recovery. At least three animals were recorded per group. **P < 0.001. E:
Fasting glucose proﬁle of wild-type (n  8), L-PANIC (n  5), and H-PANIC (n  3) mice during the entire recovery period. *P < 0.05, **P < 0.001.
(Please see http://dx.doi.org/10.2337/db07-1631 for a high-quality digital representation of this ﬁgure.)
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islets with a sharp increase of apoptotic staining suggests
that massive -cell death is about to initiate at 24 h after
treatment.
PPAR- agonist and sitagliptin treatments improve
-cell recovery in homozygous PANIC-ATTAC mice.
The stimulation of the GLP-1 axis is a powerful ap-
proach to speed up recovery in the hemizygous PANIC-
ATTAC mice. Although a -cell–speciﬁc PPAR-
knockout only showed a relatively mild phenotype (23),
recent studies suggested that PPAR- can in fact play an
important role in -cell physiology (24). To probe
whether PPAR- agonists may have an impact on recov-
ery, homozygous PANIC-ATTAC mice were treated with
a single dose of dimerizer at 0.3 g/g body wt to trigger
severe hyperglycemia. On day 8 after dimerizer treat-
ment, mice were treated with a PPAR- agonist (COOH)
(12). By day 28, fasting glucose had nearly recovered to
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DIABETES, VOL. 57, AUGUST 2008 2143baseline levels (Fig. 5A). The OGTT response also
improved signiﬁcantly (Fig. 5B), but GSIS remained
impaired (Fig. 5C). Although PPAR- agonists have a
potent impact on insulin sensitivity in peripheral tis-
sues, they also have an effect on -cells by increasing
the pancreatic insulin content, even though the differ-
ences did not reach statistical signiﬁcance (Fig. 5D). An
ITT on day 48 revealed only modest differences between
PPAR- agonist and vehicle treatments (Fig. 5E).
Whether the improvements found in glucose control are
a function of direct effects of PPAR- in -cells or reﬂect
an indirect mechanism of action of PPAR- agonist
action in adipocytes or other tissues remains to be seen.
Sitagliptin is a dipeptidyl peptidase-4 inhibitor in clinical
use, increasing active GLP-1 levels (10,13). After induction
of severe hyperglycemia, sitagliptin treatment was initial-
ized as a food additive. We found that the active GLP-1
levels were increased twofold in sitagliptin-treated ani-
mals (Fig. 5F). This was accompanied by an improved
glucose tolerance (Fig. 5G) and substantial restoration of
islet structure and morphology (Fig. 5H) (10).
PANIC-ATTAC mice display improved insulin sensi-
tivity on recovery. An additional interesting phenome-
non was unraveled when we assessed the recovered
transgenic mice. Because they had undergone several
weeks of hyperglycemia, we expected that the chronic
exposure to high glucose would have caused permanent
damage due to a “hyperglycemic memory” effect leading to
insulin resistance. However, we found that recovered
PANIC-ATTAC mice displayed signiﬁcant improvements in
insulin sensitivity in both hemizygous (Fig. 6A) and ho-
mozygous mice (Fig. 6B). Although the low concentrations
of available insulin may contribute to the increased effec-
tiveness of injected insulin, there may be additional mech-
anisms in place in light of the rather unusual but
physiological context in which the PANIC-ATTAC animals
operate.
GLUT2
/insulin
 cell number increases after -cell
recovery. The remarkable recovery of pancreatic -cells
in PANIC-ATTAC mice raises the question of what cell
type gives rise to the newly emerging -cell population. On
careful analysis of the recovering pancreas, insulin
 cells
appeared in the ducts (data not shown), which has been
suggested to be a sign for -cell neogenesis (4,25). How-
ever, we decided to focus on a different cell type that may
or may not be related to the insulin
 ductal cells. We took
advantage of the fact that animals administered high-dose
STZ generally do not recover from hyperglycemia (Fig. 6C
compared with Fig. 4F). The main route of cellular entry of
STZ is through the glucose transporter GLUT2 (26). We
reasoned that high-dose STZ administration results in
irreversible damage to the pancreas because -cell precur-
sors may also express GLUT2 and the lack of recovery is
mostly due to simultaneous elimination of both adult
-cells and precursors. In the PANIC-ATTAC mice, we are
ablating only mature, insulin
 -cells. If this is the case,
we postulated that we should be able to identify a novel
population of insulin
/GLUT2
 cells in the recovering
PANIC-ATTAC mice. This is the case (Fig. 6D). Although
in wild-type cells, GLUT2 staining is restricted to insulin

cells with very few GLUT2
/insulin
 cells, high-dose STZ
administration eliminated essentially all GLUT2
 cells.
However, in recovering PANIC-ATTAC mice, a signiﬁcant
number of GLUT2
 cells are insulin
 and PDX-1
 (Fig. 6D;
Supplementary Fig. 5). This is suggestive that a -cell
precursor pool exists that is deﬁned by GLUT2 positivity
without concomitant insulin expression. We are currently
in the process of developing an approach to isolate these
cells. Further characterization of these cells will have to
await detailed lineage tracing studies.
We found that the membrane-bound localization of
GLUT2 is lost in hyperglycemic PANIC-ATTAC animals
compared with animals that have achieved euglycemic
levels again (Fig. 6E). The predominantly intracellular
localization of GLUT2 suggests that -cells have additional
and so far uncharacterized mechanisms in place to protect
them from hyperglycemic damage that not only involves
the transcriptional downregulation of GLUT2 (27) but also
the intracellular retention of the transporter.
DISCUSSION
Here, we describe a novel mouse model allowing the
inducible ablation of -cells at any stage during the life
cycle of a mouse. Compared with several conventional
pancreas injury models, the PANIC-ATTAC mice differ in a
number of ways and offer great potential in several areas
of islet physiology.
In the PANIC-ATTAC model, the degree of apoptosis in
the -cell population can be manipulated in several ways,
by varying both the dose and the frequency of dimerizer
treatment, by transgene dosage (hemizygous vs. homozy-
gous animals), and by dietary intervention (high-fat diet
exposure). Although an aggressive treatment regimen has
the advantage of destroying a large number of -cells
rapidly, yielding uniform hyperglycemia, a moderate chal-
lenge can be used to examine the key anti-apoptotic
responses in surviving cells.
One of the most novel aspects of this model is the
dramatic recovery of -cells to levels nearly identical to
those before treatment. A number of mechanisms may
enable the -cell population to recover under these cir-
cumstances. The rather “gentle” proapoptotic approach
FIG. 4. Characterization of the homozygous PANIC-ATTAC mice. A: OGTT and pancreatic insulin content of wild-type and homozygous
PANIC-ATTAC (P/P) mice before administration of dimerizer. For OGTT, n  6 per group. For pancreatic insulin content, n  4 of wild type and
n  3 of P/P. A representative immunoﬂuorescent image for insulin (green), glucagon (red), and nuclei (blue) is shown. Scale bar  50 m. B:
OGTT and pancreatic insulin content of wild-type and P/P mice 8 days after a single treatment of dimerizer. For glucose measurements during
OGTT, seven animals were used per experimental group. The same animals were used for insulin analysis. For the pancreatic insulin content
measurement, n  6 of wild type and n  7 of P/P. A representative immunoﬂuorescent image for insulin (green), glucagon (red), and nuclei
(blue) is shown. Scale bar  50 m. *P < 0.05, **P < 0.001. C: OGTT and pancreatic insulin content of wild-type and P/P mice 64 days after
administration of dimerizer. For glucose measurements during OGTT, n  4 for wild type and n  3 for P/P. Insulin measurements were performed
on the same mice. For pancreatic insulin content, n  5 of wild type, n  3 of P/P. A representative immunoﬂuorescent image for insulin (green),
glucagon (red), and nuclei (blue) is shown. Scale bar  50 m. *P < 0.05, **P < 0.001. D: Dose-dependent ablation of -cells with dimerizer
administration. Dimerizer was injected at different concentrations into wild-type and P/P animals (low, 0.05; medium, 0.2; and high, 0.5 g/g body
wt). After 8 days, pancreatic insulin content was determined. More than three animals were recorded per treatment. **P < 0.001. E: Fasting
glucose levels of wild-type and P/P mice before dimerizer treatment, at the onset of hyperglycemia (day 8), and after recovery (day 64). At least
three animals were monitored in each group. **P < 0.001. F: Fasting glucose proﬁle of wild-type and P/P animals during recovery period. More
than three animals were used per group. *P < 0.05, **P < 0.001. G: Visualization of apoptotic -cells by TUNEL staining in wild-type, hemizygous,
and homozygous PANIC-ATTAC mice 4 and 24 h after treatment. Insulin
 -cells are showed in green, and apoptotic cells are shown in red. Scale
bar  50 m. (Please see http://dx.doi.org/10.2337/db07-1631 for a high-quality digital representation of this ﬁgure.)
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methods may minimize the inﬂammatory response in the
islets. Hyperglycemia per se seen in the PANIC-ATTAC
model may provide a more favorable environment for
-cell recovery compared with other pancreas injury mod-
els where hyperglycemia is usually accompanied by hyper-
insulinemia and dyslipidemia. Additionally, we may
preserve a potential -cell precursor pool by targeting
insulin
 cells compared with the less speciﬁc exposure to
STZ. Similar animal models have been reported by target-
ing expression of diphtheria toxin speciﬁcally in -cells
(28,29). Nir et al. (29) found a similar phenomenon of
-cell regeneration after triggering ablation in their animal
model, reporting results vastly consistent with the obser-
vations described here, further emphasizing the potential
for plasticity of -cell mass under some conditions. More
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vation has been created and characterized, which shows
signiﬁcant regeneration after -cell ablation (30).
The lack of GSIS in the recovered islets does not come
as a surprise. In rat models, hyperglycemia has been
reported to cause defective GSIS (19). Additionally, it is
possible that the newly differentiated -cells do not re-
spond to glucose effectively in the recovered islets, pre-
sumably because of the lack of a speciﬁc factor. Although
it is clear that we fail to fully reconstitute complete
functionality of -cells, this model also represents a
unique tool for testing factors and compounds that can
confer restoration of GSIS. Putative GSIS reconstitution
drugs can be used together with antidiabetes treatments
that may only restore the pancreatic insulin content (Figs.
3 and 5). The combination of improvements for both GSIS
and pancreatic insulin content is pivotal for effective glyce-
mic control. Additionally, this model can also be used to
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the restoration of GSIS, which were previously identiﬁed in
vitro to be critically involved in this process (31).
We have shown a number of “proof of concept” exam-
ples of pharmacological interventions that enhance the
recovery kinetics on a massive proapoptotic challenge.
The PANIC-ATTAC mouse model lends itself for further
applications in this area with uniform hyperglycemia and
the ability to recover. In the current study, we have used
these transgenic mice after hyperglycemia to determine
the recovery-enhancing aspects of pharmacological inter-
ventions. An equally attractive approach is to test the
anti-apoptotic protective mechanisms that may be induced
pharmacologically. Using the PANIC-ATTAC mouse
model, we are able to screen for pharmacological inter-
ventions that confer protective effects on -cells during
diabetes initiation to slow down and prevent the onset of
hyperglycemia.
The PANIC-ATTAC mouse model lends itself to addi-
tional experimental approaches for which there is cur-
rently no experimental paradigm available. Gestational
diabetes is associated with adverse effects on fetal devel-
opment during pregnancy and more importantly, increas-
ing incidence for diabetes in the offspring later in life (32).
To study gestational diabetes, glucose infusion and chem-
ical-induced hyperglycemia have been used in animals
with limitations and toxin-related complications (33,34).
Using PANIC-ATTAC mice, transgene
 animals can be
induced to become hyperglycemic during gestation, ex-
posing wild-type embryos to hyperglycemia without con-
founding factors. Additionally, to dissect the exact
contributions of hyperglycemia in utero versus hypergly-
cemic effects during lactation on future diabetes develop-
ment, wild-type pups from diabetic mothers can be
adopted by euglycemic mothers and vice versa.
Both neogenesis from precursor cells and replication
from adult -cells have been identiﬁed as the mechanism
of -cell regeneration (4,29,35). The inconsistencies may
be due to the differences in experimental models and
conditions. Here, we deﬁne a novel cell population that
can be observed at high frequency in recovering PANIC-
ATTAC islets. This population is characterized by high
level expression of GLUT2, yet these cells have not (or not
yet) induced the expression of insulin. We appreciate that
we have not formally demonstrated that these cells are
precursors for -cells, and it is possible that they are a
curiosity of this particular system. We did not ﬁnd signif-
icant number of GLUT2
/insulin
 cells in wild-type con-
trol animals, which argues against this cell population as a
resident cell type in islets. However, it is clear that STZ
administration at higher concentrations completely elimi-
nates this cell population, and this might be a potential
reason to prevent recovery of the islets. The widespread
presence of these cells in the recovering PANIC-ATTAC
islets is intriguing, but it is also consistent with the
ﬁnding that GLUT2
 epithelial cells have been postu-
lated to give rise to adult -cells during development
(36). Additionally, in the ductal ligation model of pan-
creas injury, increased proliferation of GLUT2
 cells
has been reported in pancreatic ducts (25). We are
currently devoting signiﬁcant efforts toward the isola-
tion of this cell population.
In summary, the PANIC-ATTAC mice provide an induc-
ible model of -cell loss with the ability of -cell recovery
and a host of novel aspects that most of the previously
described pancreas injury models failed to display to date.
Applications of the PANIC-ATTAC mouse model in several
areas of islet research may provide an ideal system to
improve our understanding of GSIS, gestational diabetes,
and the deﬁnition of novel -cell precursors.
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